
1. j infect dis. 2013 feb 1;207(3):511-9. doi: 10.1093/infdis/jis709. epub 2012 nov 
29.

molecular basis allele-specific efficacy blood-stage malaria vaccine:
vaccine development implications.

ouattara a(1), takala-harrison s, thera ma, coulibaly d, niangaly a, saye r, tolo
y, dutta s, heppner dg, soisson l, diggs cl, vekemans j, cohen j, blackwelder wc,
dube t, laurens mb, doumbo ok, plowe cv.

author information: 
(1)malaria research training center, university sciences, techniques and
technology, bamako, mali.

the disappointing efficacy blood-stage malaria vaccines may explained in
part allele-specific immune responses directed polymorphic
epitopes blood-stage antigens. fmp2.1/as02(a), blood-stage candidate vaccine
based apical membrane antigen 1 (ama1) 3d7 strain plasmodium
falciparum, allele-specific efficacy clinical malaria phase ii
trial malian children. assessed cross-protective efficacy the
malaria vaccine inferred polymorphic amino acid positions ama1 
the targets protective allele-specific immune responses. fmp2.1/as02(a) had
the highest efficacy ama1 alleles identical 3d7
vaccine-type allele 8 highly polymorphic amino acid positions cluster 1
loop (c1l) differed 3d7 elsewhere molecule. comparison the
incidence vaccine-type alleles vaccination malaria
vaccine control groups examination patterns allele change at
polymorphic positions consecutive malaria episodes suggest highly
polymorphic amino acid position 197 c1l critical determinant of
allele-specific efficacy. results indicate multivalent ama1 vaccine 
with broad efficacy could include limited set key alleles this
extremely polymorphic antigen.

doi: 10.1093/infdis/jis709 
pmcid: pmc3537449
pmid: 23204168  [indexed medline]

